Related Experiment Video
Updated: Jan 14, 2026

Application of a New Mesh Fixation Method in Laparoscopic Incisional Hernia Repair
Published on: December 23, 2022
Do Anticoagulants Have an Impact on the Clinical Outcomes of Ventral Hernia Repair? A Systematic Review and
Caroline Daleaste Wilmsen1, Augusto Graziani E Sousa2, Raquel Nogueira3
1Universidade do Planalto Catarinense, Lages, Brazil.
Insights
Anticoagulation therapy after ventral hernia repair (VHR) increases risks of bleeding complications and reoperations. However, transfusion rates were similar, and further research on minimally invasive surgery is needed.
Area of Science:
- General Surgery
- Surgical Outcomes
- Pharmacology
Background:
- Ventral hernia repair (VHR) is a common surgical procedure.
- Anticoagulation (AC) therapy is often necessary for various medical conditions.
- The impact of AC on VHR outcomes requires clarification.
Purpose of the Study:
- To systematically review and meta-analyze the effect of AC therapy on clinical outcomes following VHR.
- To assess risks of bleeding, reoperation, and other complications in patients on AC.
Main Methods:
- Comprehensive search of PubMed, Cochrane, and Embase databases.
- Inclusion of studies comparing AC therapy use post-VHR.
- Analysis of bleeding-related reoperation, hemorrhagic/thrombotic complications, length of stay, and transfusion rates using random-effects model.
Main Results:
- Analysis of 4 studies with 41,868 patients (4804 on AC).
- Increased hemorrhagic/thrombotic complications (RR: 2.3) and bleeding-related reoperations (RR: 6.5) in AC group.
- Prolonged hospital stays (1.69 days longer) observed in patients on AC therapy.
Conclusions:
- AC therapy post-VHR is linked to higher rates of hemorrhagic/thrombotic complications and bleeding-related reoperations.
- Hospitalization duration is extended for patients on AC therapy.
- Transfusion rates did not significantly differ; further investigation into minimally invasive surgery (MIS) impact is warranted.
Aim:
This study aims to perform a comprehensive systematic review and meta-analysis to evaluate the impact of anticoagulation (AC) therapy on clinical outcomes during ventral hernia repair (VHR).
Materials And Methods:
A thorough online search was conducted using PubMed, Cochrane, and Embase databases. Studies comparing the use of AC therapy following VHR were included. The results analyzed were bleeding-related reoperation, hemorrhagic/thrombotic complications, length of stay, and transfusion rates. Statistical analysis was performed with Review Manager 5.4 using a random-effects model.
Results:
From 1278 records, 4 studies were included, encompassing 41,868 patients (anticoagulants use = 4804; no AC = 32,649), with 25% on anticoagulant therapy submitted to minimally invasive surgery (MIS). Additionally, 90% of patients using anticoagulants underwent mesh placement. Overall analysis showed increased hemorrhagic/thrombotic complications (risk ratios [RR]: 2.3; 95% confidence interval [CI]: 1.13-4.8; P = .02), bleeding-related reoperation (RR: 6.5; 95% CI: 4.3-9.9; P < .00001), and longer hospital stays (mean difference: 1.69 days; 95% CI: .66 to 2.72 days; P = .001) in patients using anticoagulant medications. However, there was no increased risk of transfusion (RR: 2.14; 95% CI: 0.58-7.95; P = .26) between groups.
Conclusions:
The use of anticoagulant therapy following VHR is associated with increased hemorrhagic/thrombotic complications, bleeding-related reoperations, prolonged hospitalization, and similar transfusion rates. Further research is still required to validate these findings and explore the impact of MIS on anticoagulated patients following VHR.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Aneurysm IV: Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins

